BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 2102029)

  • 1. [Effectiveness and tolerance of long-term uricosuric treatment].
    Berg H
    Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Matzkies F
    Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
    Matzkies F
    Fortschr Med; 1983 May; 101(20):953-9. PubMed ID: 6873850
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
    Arntz HR; Dreykluft HR; Leonhardt H
    Fortschr Med; 1979 Jul; 97(27):1212-4. PubMed ID: 457017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 12. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Mertz DP
    Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
    [No Abstract]   [Full Text] [Related]  

  • 13. [The use of Allomaron in treating hyperuricemia].
    Balkarov IM
    Ter Arkh; 1994; 66(1):40-2. PubMed ID: 8146793
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro.
    Inokuchi T; Tsutsumi Z; Takahashi S; Ka T; Yamamoto A; Moriwaki Y; Masuzaki H; Yamamoto T
    Horm Metab Res; 2009 Apr; 41(4):327-32. PubMed ID: 19048458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP
    MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
    Gröbner W; Walter-Sack I; de Vries JX
    Eur J Med Res; 1998 Feb; 3(1-2):77-80. PubMed ID: 9512972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Isolated or combined drug therapy of hyperuricemia?].
    Mertz DP
    Dtsch Med Wochenschr; 1977 Jul; 102(30):1096-7. PubMed ID: 891391
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.